Power wheelchair — group 2 denied as experimental or investigational by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## Why UnitedHealthcare Denies a Group 2 Power Wheelchair as Experimental

An "experimental or investigational" denial means UHC has concluded that the requested equipment or a specific feature of it lacks sufficient clinical evidence to be considered established medical practice under its coverage criteria. For Group 2 power wheelchairs, this denial type is relatively uncommon for the wheelchair itself — which is a well-established category of durable medical equipment (DME) — but may arise when the denial targets a specific advanced feature (such as a specialized seating or positioning system, power tilt/recline, or other add-on) that UHC classifies as investigational.

## Why This Denial Is Highly Appealable

Group 2 complex rehabilitation power wheelchairs and their standard components have extensive clinical literature supporting their use in patients with permanent mobility limitations. If UHC is denying the wheelchair itself as experimental, that classification is almost certainly erroneous and should be challenged directly. If the denial targets a specific feature or component, the appeal should focus on the clinical necessity of that feature for your documented condition — peer-reviewed literature and professional society guidance (such as that from the Rehabilitation Engineering and Assistive Technology Society of North America, RESNA) can be cited by your prescriber to rebut the experimental characterization.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / state law): File within the deadline on your denial notice. An experimental/investigational denial is a clinical-basis denial and receives full-and-fair review.
• External review (ACA §2719): Experimental/investigational denials are specifically subject to independent external review — this is one of the categories Congress targeted. File within approximately four months of final internal denial.
• Expedited review: If your mobility condition creates urgent functional or safety risk, request expedited review at both levels.
• Medicare Advantage: If applicable, CMS has specific coverage standards for power mobility devices that may override a plan's experimental determination.

## Documentation to Gather

1. Prescriber clinical evidence letter: Citing peer-reviewed literature and professional society guidance supporting the medical necessity and clinical establishment of the Group 2 power wheelchair (or the contested feature) for patients with your diagnosis. 2. Functional mobility assessment: By a licensed physical or occupational therapist, documenting your specific impairments and why Group 2 power mobility (or the contested feature) is the clinically appropriate solution. 3. Diagnosis documentation: Chart records confirming your mobility-limiting diagnosis, its permanence, and severity. 4. UHC's experimental criteria: Obtain the exact clinical policy UHC relied on. If it cites specific evidence thresholds, your prescriber's letter should address those thresholds. 5. CMS/LCD reference: The applicable Medicare Local Coverage Determination (LCD) for power mobility devices is a strong reference even for commercial plans — it establishes that this category is clinically recognized.

## Criteria-Mapping Structure

Map UHC's experimental/investigational criteria to your evidence:

| UHC Experimental Criterion | Your Rebuttal Evidence | |---|---| | Insufficient clinical evidence for use | [Peer-reviewed literature cited by prescriber, society guideline] | | Not recognized as standard of care | [RESNA or equivalent society guidance, CMS LCD reference] | | Feature is contested as investigational | [Clinical necessity of specific feature per therapist assessment] | | Prescriber attestation | [Medical necessity letter from Dr. XX, dated XX] |

Challenge the experimental classification directly in the appeal's opening paragraph — state that Group 2 power wheelchairs are a recognized, established category of complex rehabilitation technology.